PARIS, France I July 15, 2013 I Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School (Harvard).
Under the terms of the agreement, Ipsen will fund Harvard research for at least three years with the aim to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of serious neurologic diseases.
The collaboration will combine Harvard’s discovery platform and botulinum toxins engineering expertise with Ipsen’s know-how in drug discovery and pharmaceutical R&D.
Ipsen will have exclusive worldwide rights on any candidate recombinant toxin stemming from the collaboration. Ipsen will be responsible for the development and marketing of the new toxins and will make associated upfront, milestones and royalty payments to Harvard.
Claude Bertrand, Executive Vice president R&D, Chief Scientific Officer at Ipsen added: “Ipsen is very pleased to combine its expertise with such a renowned research institution as Harvard. This collaboration further strengthens Ipsen’s position in biotechnology as a major player focused on the discovery and development of therapeutic toxins to provide innovative therapies for patients with serious neurologic disorders.”
“Our collaboration with Ipsen to discover novel engineered botulinum toxins will greatly facilitate our research efforts to potentially bring novel therapeutics to the benefit of patients suffering from highly debilitating conditions,” said Dr. Min Dong, Instructor in Microbiology and Immunobiology at the New England Primate Research Center and Department of Microbiology and Immunobiology of Harvard Medical School.
About Harvard University’s office of technology development
Harvard’s Office of Technology Development (OTD) is responsible for all activities pertaining to the evaluation, patenting and licensing of new inventions and discoveries made at Harvard University and Harvard Medical School. OTD also serves to further the development of Harvard technologies through the establishment of sponsored research collaborations with industry. OTD’s mission is to promote the public good by fostering innovation and translating new inventions made at Harvard into useful products available and beneficial to society.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total turnover exceeding €1.27 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: neurology / Dysport®, endocrinology / Somatuline® and uro-oncology / Decapeptyl®. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,900 employees. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
SOURCE: Ipsen
Post Views: 248
PARIS, France I July 15, 2013 I Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it has initiated a research and development collaboration on novel engineered botulinum toxins with Harvard Medical School (Harvard).
Under the terms of the agreement, Ipsen will fund Harvard research for at least three years with the aim to discover, evaluate and develop novel engineered recombinant botulinum toxins for the treatment of serious neurologic diseases.
The collaboration will combine Harvard’s discovery platform and botulinum toxins engineering expertise with Ipsen’s know-how in drug discovery and pharmaceutical R&D.
Ipsen will have exclusive worldwide rights on any candidate recombinant toxin stemming from the collaboration. Ipsen will be responsible for the development and marketing of the new toxins and will make associated upfront, milestones and royalty payments to Harvard.
Claude Bertrand, Executive Vice president R&D, Chief Scientific Officer at Ipsen added: “Ipsen is very pleased to combine its expertise with such a renowned research institution as Harvard. This collaboration further strengthens Ipsen’s position in biotechnology as a major player focused on the discovery and development of therapeutic toxins to provide innovative therapies for patients with serious neurologic disorders.”
“Our collaboration with Ipsen to discover novel engineered botulinum toxins will greatly facilitate our research efforts to potentially bring novel therapeutics to the benefit of patients suffering from highly debilitating conditions,” said Dr. Min Dong, Instructor in Microbiology and Immunobiology at the New England Primate Research Center and Department of Microbiology and Immunobiology of Harvard Medical School.
About Harvard University’s office of technology development
Harvard’s Office of Technology Development (OTD) is responsible for all activities pertaining to the evaluation, patenting and licensing of new inventions and discoveries made at Harvard University and Harvard Medical School. OTD also serves to further the development of Harvard technologies through the establishment of sponsored research collaborations with industry. OTD’s mission is to promote the public good by fostering innovation and translating new inventions made at Harvard into useful products available and beneficial to society.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total turnover exceeding €1.27 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by three franchises: neurology / Dysport®, endocrinology / Somatuline® and uro-oncology / Decapeptyl®. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,900 employees. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
SOURCE: Ipsen
Post Views: 248
